Loading...

PharmAust Limited

PAA.AXASX
Healthcare
Biotechnology
A$0.23
A$0.02(6.98%)

PharmAust Limited (PAA.AX) Stock Competitors & Peer Comparison

See (PAA.AX) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
PAA.AXA$0.23+6.98%111.9M-11.50-A$0.02N/A
CSL.AXA$271.11+0.19%131.7B32.73A$8.31+1.56%
TLX.AXA$20.68-1.94%7B136.93A$0.15N/A
MSB.AXA$2.45-1.61%3.2B-12.45-A$0.20N/A
NEU.AXA$16.63+0.91%2.1B15.32A$1.09N/A
CU6.AXA$4.33+2.85%1.4B-27.06-A$0.16N/A
OPT.AXA$0.60+0.00%738.8M-1.40-A$0.43N/A
PYC.AXA$1.27+0.79%732M-11.41-A$0.11N/A
CUV.AXA$12.83+5.95%627M16.25A$0.77+0.40%
IMM.AXA$0.27+1.92%396.3M-9.00-A$0.03N/A
Showing 1 to 10 of 57 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

PAA.AX vs CSL.AX Comparison July 2025

PAA.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PAA.AX stands at 111.9M. In comparison, CSL.AX has a market cap of 131.7B. Regarding current trading prices, PAA.AX is priced at A$0.23, while CSL.AX trades at A$271.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PAA.AX currently has a P/E ratio of -11.50, whereas CSL.AX's P/E ratio is 32.73. In terms of profitability, PAA.AX's ROE is -0.87%, compared to CSL.AX's ROE of +0.15%. Regarding short-term risk, PAA.AX is more volatile compared to CSL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for PAA.AX.Check CSL.AX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;